RT Journal
A1 Jacobs JM, Stessman J
T1 Dabigatran: Do we have sufficient data?: comment on “dabigatran association with higher risk of acute coronary events”
JF Archives of Internal Medicine
JO Archives of Internal Medicine
YR 2012
FD March 12
VO 172
IS 5
SP 403
OP 404
DO 10.1001/archinternmed.2011.1721
UL http://dx.doi.org/10.1001/archinternmed.2011.1721
AB 
The explosion of literature on dabigatran draws heavily from the 7 RCTs included in the meta-analysis of Uchino and Hernandez.1 Dabigatran is the primary contender among several to have reached the finish line of phase 3 trials largely unscathed and has gained approval both in the United States and Europe for prophylaxis of VTE and stroke in patients with nonvalvular AF.